🟢 Anixa Biosciences is trading 6% up today after Australian patent acceptance for breast cancer vaccine

Anixa Biosciences is trading 5.6% up now at $3.37 after announcing Australian patent acceptance for its novel breast cancer vaccine platform.

• The new patent expands the company's global intellectual property protection, adding to existing patents already secured in the U.S., Europe, China, and Japan.
• Investors are responding to the strengthened IP portfolio surrounding the Cleveland Clinic–licensed technology targeting triple-negative breast cancer.
• The upward move coincides with a broader lift in U.S. equity markets as cooling inflation data supports investor appetite for risk assets.